产品
编 号：F528735
分子式：C19H29ClN2O4
分子量：384.9
分子式：C19H29ClN2O4
分子量：384.9
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
480
In-stock
1g
784
In-stock
5g
2240
In-stock
结构图
CAS No: 93793-83-0
产品详情
生物活性：
Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity.
体内研究：
Roxatidine Acetate Hydrochloride (0-300 mg/kg; p.o.; 26 days) suppressed growth of Colon 38 tumor implants in mice.Roxatidine Acetate Hydrochloride (oral gavage; 20?mg/kg; single dose) inhibits Compound 48/80-increased TNF-α, IL-6, and IL-1β production and mRNA expression. Additionally, Roxatidine Acetate Hydrochloride decreases the compound 48/80-induced degradation of procaspase-1 and appearance of the corresponding cleaved bands in mice.Animal Model:Male C57BL/6 Colon 38-bearing mice (8-week-old, 20 – 22 g)
Dosage:30, 100, and 300 mg/kg per day, 1 ml/100 g body weight
Administration:Oral administration, 29 days beginning 3 days before Colon 38 implantation or 26 days beginning concomitantly with Colon 38 implantation
Result:Suppressed growth of Colon 38 tumor implants in a dose-related manner after day 26. Suppressed VEGF levels in tumor tissue and significantly decreased serum VEGF levels.
Animal Model:ICR male mice (6 weeks old)
Dosage:20?mg/kg
Administration:Oral gavage; 20?mg/kg; single dose
Result:Suppressed compound 48/80-induced allergic inflammation in anaphylactic animal model.
体外研究：
Roxatidine Acetate Hydrochloride (0-120 μM, 1 h) suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.Roxatidine Acetate Hydrochloride (6.25 ?μM, 12.5?μM, and 25?μM; pre-treatment for 30?min) suppresses the PMACI-induced activation of p38 MAPK, but does not affect the phosphorylation of ERK or JNK. The total ERK 1/2, JNK, and p38 MAPK levels are unaffected by roxatidine in human mast-cells-1 (HMC-1) cells.
Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity.
体内研究：
Roxatidine Acetate Hydrochloride (0-300 mg/kg; p.o.; 26 days) suppressed growth of Colon 38 tumor implants in mice.Roxatidine Acetate Hydrochloride (oral gavage; 20?mg/kg; single dose) inhibits Compound 48/80-increased TNF-α, IL-6, and IL-1β production and mRNA expression. Additionally, Roxatidine Acetate Hydrochloride decreases the compound 48/80-induced degradation of procaspase-1 and appearance of the corresponding cleaved bands in mice.Animal Model:Male C57BL/6 Colon 38-bearing mice (8-week-old, 20 – 22 g)
Dosage:30, 100, and 300 mg/kg per day, 1 ml/100 g body weight
Administration:Oral administration, 29 days beginning 3 days before Colon 38 implantation or 26 days beginning concomitantly with Colon 38 implantation
Result:Suppressed growth of Colon 38 tumor implants in a dose-related manner after day 26. Suppressed VEGF levels in tumor tissue and significantly decreased serum VEGF levels.
Animal Model:ICR male mice (6 weeks old)
Dosage:20?mg/kg
Administration:Oral gavage; 20?mg/kg; single dose
Result:Suppressed compound 48/80-induced allergic inflammation in anaphylactic animal model.
体外研究：
Roxatidine Acetate Hydrochloride (0-120 μM, 1 h) suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.Roxatidine Acetate Hydrochloride (6.25 ?μM, 12.5?μM, and 25?μM; pre-treatment for 30?min) suppresses the PMACI-induced activation of p38 MAPK, but does not affect the phosphorylation of ERK or JNK. The total ERK 1/2, JNK, and p38 MAPK levels are unaffected by roxatidine in human mast-cells-1 (HMC-1) cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备